Laura Eleanor MacConaill, Ph.D.
This page shows the publications co-authored by Laura MacConaill and Nikhil Wagle.
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012 Jan; 2(1):82-93.
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011 Aug 01; 29(22):3085-96.
Genomic Characterization of de novo Metastatic Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):1105-1118.
Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2565-2572.
Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3.
The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med. 2016 07 26; 8(1):79.
Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014 Jun; 20(6):682-8.
Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013 Nov 01; 119(21):3776-83.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.